Arbutus Biopharma Corp (ABUS)

NASDAQ • Healthcare

$4.2

-$0 (-0.2%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$4.17

Previous Close$4.2

Day Range$4.12 - $4.22

Avg. Volume (3M)6.2M

Market Cap$832M

P/E Ratio5.3

52 Week Range

$3.5$5.45

Next EarningsIn 22 daysNov 16, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$1M100%

Gross Profitminus cost of goods$1M100%

Fundamentals & Financials

Revenue (TTM)

$181.7M

Net Income (TTM)

$153M

EPS (TTM)

$0.79

ROA (TTM)

55.85%

Current Ratio

81.42

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+150.0%Q3 2025$0.01

+28.6%Q4 2025-$0.04

+71.5%Q1 2026-$0.01

+3000.0%Q2 2026$0.87

-50.0%Q3 2026-$0.03

Nov 16

in 22 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -50.0%

Arbutus Biopharma’s preliminary results for the second fiscal quarter of 2026 pointed to a loss, with EPS of -$0.03 versus $0.01 a year ago, as the company continues to fund development work in chronic hepatitis B programs such as imdusiran and AB-101; the update was reported August 12, 2026. Profitability remained negative, with operating income of -roughly $6.0 million, and cash generation also ran below zero, with negative operating cash flow of about $6.0 million. Looking ahead, next-period consensus calls for EPS of -$0.02 on revenue of $1.0 million.

Next report — what to expect

Arbutus Biopharma Corp (ABUS) is set to report on November 16, 2026. The next-period consensus calls for EPS of -$0.023 on revenue of $1.0 million; for trailing context, revenue was -90.6% year over year last quarter. ABUS has beaten EPS in 5 of 8 most recent quarters.

View full earnings history

About Arbutus Biopharma Corp

Arbutus Biopharma Corp is a NASDAQ-listed biotechnology company that develops novel therapeutics for infectious disease, with its work centered on chronic hepatitis B. In FY2025, the company recorded $14.1 million in revenue. Its programs and supporting technology are based in the United States from Warminster, Pennsylvania.

Name

Arbutus Biopharma Corp

CEO

Lindsay Androski

Website

www.arbutusbio.com

Industry

Healthcare

Year Founded

2005

Employees

Today's Snapshot

AI-generated

ABUS ended the day slightly lower at 4.20, while its sector was weaker.

Trading Volume

Below 10d avg (2.7M)

vs S&P 500 Today

Moderate Outperformance

+0.28%

Updated: October 23, 2026 at 20:25 UTC

ABUS Headlines

Arbutus plans US$230m share tender offer

August 21, 2026

3 min read

View All News

Technical Indicators

0 Buy3 Neutral5 Sell

ABUS displays a weak technical profile with the current price beneath most moving averages, including the 200-day, and momentum nearly flat to negative; MACD is marginally below zero while RSI and other oscillators are noncommittal. ADX above 30 indicates a notable trend strength to the downside, and on-balance volume reflects distribution. Volatility is modest with a small ATR and the pivot sits just above the market. Technical takeaway: Strong sell — trend strength, negative volume flow and price below major averages point to continued pressure.

All signals

EMA (5 indicators)$4.25 - $4.61
Sell
RSI (14)37.76
Neutral
Stochastic %K (14, 3, 3)20.95
Neutral
MACD Level (12, 26)-0.17
Neutral

Peers & Related Assets

ALNYAlnylam Pharmaceuticals, Inc.

$224.03-1.4%

ARWRArrowhead Pharmaceuticals, Inc.

$58.02-0.6%

VIRVir Biotechnology, Inc.

$10.57+1.3%

ENTAEnanta Pharmaceuticals, Inc.

$11.64+0.2%

AVIRAtea Pharmaceuticals, Inc.

$4.04-0.3%

SLNSilence Therapeutics plc

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.